Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuclue 40 mg for chronic cough due to gastroesophageal reflux disease (GERD)
KCT0007746Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fexuprazan in gastroesophageal reflux disease (GERD), chronic cough, sponsored by Daewoong Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)chronic cough
Beyond the preview
Go deeper on KCT0007746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007746.